Business · Companies · 1 hr ago
Celltrion reports strong drug sales in Asia and Latin America
South Korean drugmaker Celltrion says its sales are growing in Asia and Latin America.
In Japan, its autoimmune disease drug Remsima held 48% of the infliximab market in July, making it the top-prescribed infliximab medicine.
Celltrion also reported high shares for its cancer drugs in Japan and for several products in Singapore, Hong Kong, Thailand and Malaysia.
In Latin America, Remsima held about 60% of Brazil’s private market, while some Celltrion products had shares above 80% in other countries.
The company says its local sales operations support this growth, and it operates in 43 countries, including 13 in Asia and Latin America.
Celltrion plans more launches across the regions, including Remsima SC in Japan next year and other follow-on products in several Asian and Latin American markets.
Celltrion said its medicines have gained high market shares in major Asian and Latin American markets.
In Japan, Remsima reached a 48% share of infliximab prescriptions in July and ranked first.
In the first quarter, Remsima held the leading share in Singapore, Hong Kong, Thailand and Malaysia.
Celltrion reported Remsima held about 60% of Brazil’s private market.
The company attributed the sales performance to its expansion of direct-sales infrastructure and said it plans to broaden its product portfolio.
- Who
- Celltrion, a South Korean pharmaceutical company.
- What
- The company reported high market shares for its medicines in Asian and Latin American markets.
- When
- Celltrion announced the results on October 20, 2026; the reported market shares refer to different periods, including the first quarter and July.
- Where
- Major markets in Asia and Latin America, including Japan, Singapore and Brazil.
- Why
- Celltrion said its expanded direct-sales infrastructure and local business strategy contributed to the results.
This story does not have two clearly opposing sides.
Remsima held leading market shares in Singapore, Hong Kong, Thailand and Malaysia.
Remsima reached a 48% share of infliximab prescriptions in Japan and ranked first.
Celltrion operated subsidiaries in 43 countries, including 13 in key growth markets such as Asia and Latin America.
Celltrion announced its sales and market-share results.
- Japan Remsima share
- 48% in July 2026
- Japan Herceptin and Vegzelma shares
- 78% and 64%, respectively
- Singapore Remsima share
- 93% in the first quarter of 2026
- Brazil Remsima share
- About 60% of the private market
- Celltrion subsidiaries
- 43 countries in the third quarter of 2026, including 13 in Asia and Latin America
1 source
What people are saying
Japan is a market with a structure centered on traditional pharmaceutical companies and high barriers to entry.
We have expanded our market entry through a sales strategy combining local partnerships and direct-sales capabilities, and achieving the top market share this time demonstrates the strength of our products and the results of our local business strategy.